KRAS and neoplasm: The increased plasma-circulating tumor DNA (ctDNA) of KRAS-A146 mutation noticed high plasma ctDNA levels of TP53, telomerase reverse transcriptase (TERT), and PIK3CA, which indicates the association of high tumor burden with A146 mutation [145].